WO2024062098A1 - Virus de la paraviccine recombinant codant pour l'interleukine-12 - Google Patents
Virus de la paraviccine recombinant codant pour l'interleukine-12 Download PDFInfo
- Publication number
- WO2024062098A1 WO2024062098A1 PCT/EP2023/076224 EP2023076224W WO2024062098A1 WO 2024062098 A1 WO2024062098 A1 WO 2024062098A1 EP 2023076224 W EP2023076224 W EP 2023076224W WO 2024062098 A1 WO2024062098 A1 WO 2024062098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pcpv
- nucleic acid
- composition
- cancer
- amino acid
- Prior art date
Links
- 241000621172 Pseudocowpox virus Species 0.000 title claims abstract description 202
- 108010065805 Interleukin-12 Proteins 0.000 title claims description 98
- 102000013462 Interleukin-12 Human genes 0.000 title claims description 98
- 229940117681 interleukin-12 Drugs 0.000 title claims description 91
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 98
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 98
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 86
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 81
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 78
- 229920001184 polypeptide Polymers 0.000 claims abstract description 75
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 57
- 230000003612 virological effect Effects 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 230000000890 antigenic effect Effects 0.000 claims abstract description 18
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 238000009169 immunotherapy Methods 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 105
- 239000000427 antigen Substances 0.000 claims description 62
- 108091007433 antigens Proteins 0.000 claims description 62
- 102000036639 antigens Human genes 0.000 claims description 62
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 241000700605 Viruses Species 0.000 claims description 42
- 150000001413 amino acids Chemical group 0.000 claims description 32
- 241000282414 Homo sapiens Species 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 18
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 18
- 238000003780 insertion Methods 0.000 claims description 18
- 230000037431 insertion Effects 0.000 claims description 18
- 230000028327 secretion Effects 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 15
- 102000004127 Cytokines Human genes 0.000 claims description 14
- 108090000695 Cytokines Proteins 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 13
- 238000012546 transfer Methods 0.000 claims description 13
- 230000002950 deficient Effects 0.000 claims description 12
- 230000002519 immonomodulatory effect Effects 0.000 claims description 12
- 230000001575 pathological effect Effects 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 10
- 108700005077 Viral Genes Proteins 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 108010047761 Interferon-alpha Proteins 0.000 claims description 7
- 102000006992 Interferon-alpha Human genes 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 7
- 108700020796 Oncogene Proteins 0.000 claims description 6
- 241000700618 Vaccinia virus Species 0.000 claims description 6
- 230000032823 cell division Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000037452 priming Effects 0.000 claims description 6
- 230000004565 tumor cell growth Effects 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 5
- 102000019034 Chemokines Human genes 0.000 claims description 5
- 238000013459 approach Methods 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 230000002601 intratumoral effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 210000001944 turbinate Anatomy 0.000 claims description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 3
- 230000006801 homologous recombination Effects 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 2
- 206010069754 Acquired gene mutation Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108091029795 Intergenic region Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102000003735 Mesothelin Human genes 0.000 claims description 2
- 108090000015 Mesothelin Proteins 0.000 claims description 2
- 102100034256 Mucin-1 Human genes 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 102000043276 Oncogene Human genes 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 230000006052 T cell proliferation Effects 0.000 claims description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 201000007180 bile duct carcinoma Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229940047120 colony stimulating factors Drugs 0.000 claims description 2
- 238000000315 cryotherapy Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 238000001415 gene therapy Methods 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 101150106093 gpt gene Proteins 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 208000029824 high grade glioma Diseases 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000011614 malignant glioma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 238000001565 modulated differential scanning calorimetry Methods 0.000 claims description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000002428 photodynamic therapy Methods 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 239000006152 selective media Substances 0.000 claims description 2
- 230000037439 somatic mutation Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
- 102000004533 Endonucleases Human genes 0.000 claims 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 24
- 238000002255 vaccination Methods 0.000 abstract description 9
- 230000002062 proliferating effect Effects 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 239000013598 vector Substances 0.000 description 35
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 210000001744 T-lymphocyte Anatomy 0.000 description 28
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 25
- 210000000822 natural killer cell Anatomy 0.000 description 18
- 241001529936 Murinae Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 241000700639 Parapoxvirus Species 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000004988 splenocyte Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 102000053602 DNA Human genes 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 101000623261 Trypanosoma brucei brucei Uncharacterized 25.6 kDa protein in aldolase locus Proteins 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 241000341655 Human papillomavirus type 16 Species 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 5
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229940021747 therapeutic vaccine Drugs 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 210000002845 virion Anatomy 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000006023 anti-tumor response Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000002445 nipple Anatomy 0.000 description 4
- 230000000174 oncolytic effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000712083 Canine morbillivirus Species 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283898 Ovis Species 0.000 description 3
- 206010033976 Paravaccinia Diseases 0.000 description 3
- 241000700625 Poxviridae Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 241000700565 Swinepox virus Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 241000700635 Orf virus Species 0.000 description 2
- 241001427617 Pyrophorus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000913725 Yaba-like disease virus Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000011815 naïve C57Bl6 mouse Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 230000001173 tumoral effect Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102100039396 C-X-C motif chemokine 16 Human genes 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000700628 Chordopoxvirinae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000008034 Contagious Ecthyma Diseases 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 241001531260 Cotia virus Species 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000889133 Homo sapiens C-X-C motif chemokine 16 Proteins 0.000 description 1
- 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025305 Integrin alpha-2 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101150064776 Msln gene Proteins 0.000 description 1
- 101000576803 Mus musculus Mesothelin Proteins 0.000 description 1
- 241000700562 Myxoma virus Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010031071 Orf Diseases 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011263 bladder neck cancer Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000002873 global sequence alignment Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000020298 milker nodule Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100001222 nononcogenic Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 102220080600 rs797046116 Human genes 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24241—Use of virus, viral particle or viral elements as a vector
- C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to the field of viral immunotherapy.
- the invention concerns a novel recombinant pseudocowpox virus (PCPV) comprising a nucleic acid molecule inserted in its genome and encoding an interleukine-12, composition thereof as well as their therapeutic use for preventive or treating diseases, and, notably, proliferative diseases like cancers.
- PCPV pseudocowpox virus
- the present invention also provides methods for generating and amplifying such a PCPV and a method for eliciting or stimulating and/or re-orienting an immune response using such a PCPV.
- the recombinant PCPV according to the invention further encodes for a heterologous antigenic polypeptide.
- the invention may be largely used for the therapeutic vaccination.
- Immunotherapy seeks to boost the host's immune system to help the body to eradicate pathogens and abnormal cells. Widely used in traditional vaccination, immunotherapy is also being actively investigated as a potential modality for treating severe, chronic, or life-threatening diseases in an attempt to stimulate specific and innate immune responses. A vast number of immunotherapeutics have been described in the literature for decades.
- VV vaccinia virus
- TG4001 is an investigational therapeutic vaccine based on a non-propagative, highly attenuated Vaccinia vector, the modified vaccinia virus Ankara (MVA), which is engineered to express HPV16 antigens (E6 & E7) and an adjuvant (IL-2).
- MVA modified vaccinia virus Ankara
- IL-2 an adjuvant
- TG4001 is designed to have a two-pronged antiviral approach: to alert the immune system specifically to cells presenting the HPV16 E6 and E7 antigens, that can be found in HPV16-related tumors, and to further stimulate the infection-clearing activity of the immune system through interleukin 2 (IL-2).
- IL-2 interleukin 2
- TG4001 has been administered to more than 300 individuals, demonstrating good safety and promising efficacy results.
- TG4001 Its mechanism of action and good safety profile make TG4001 an excellent candidate for combinations with other therapies in HPV-mediated solid tumors.
- This therapeutical cancer vaccine is part of a phase lb/ll trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies (ClinicalTrials.gov identifier NCT03260023).
- TG4050 Another MVA-based viral vector is the TG4050 product.
- This virus-based therapeutic vaccine is an individualized immunotherapy that encodes neoantigens (patient-specific mutations).
- TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens.
- This individualized immunotherapy is developed and produced for each patient (WO2018/234506).
- TG4050 entered into a phase 1-2 clinical trial for patients with ovarian or head and neck cancers (ClinicalTrials.gov Identifiers NCT04183166 and NCT0839524 ; Malone et al.
- Parapoxviruses represent different candidates that can be used in vector vaccines.
- Parapoxvirus belongs to the family Poxviridae and the subfamily Chordopoxvirinae. Parapoxviruses are commonly known as causative agents of dermal diseases in ruminants, leading to papular stomatitis and contagious pustular dermatitis, especially in the regions of the lips, nostrils, oral mucosa, and teats. Like other members of the Poxviridae family, parapoxvirus are relatively large and enveloped double-stranded DNA viruses with ovoid geometries that can infect vertebrates including a wide selection of mammals and humans.
- Parapoxviruses have a unique spiral coat that distinguishes them from other poxviruses.
- viral replication of parapox is cytoplasmic. Entry into the host cell is achieved by attachment of the viral proteins to host glycosaminoglycans (GAGs) that mediates endocytosis of the virus into the host cell. Fusion with the plasma membrane permits to release the core into the host cytoplasm.
- GAGs host glycosaminoglycans
- Early genes are transcribed in the cytoplasm by viral RNA polymerase. Early expression begins at 30 minutes postinfection. Intermediate phase triggers genomic DNA replication at approximately 100 minutes post- infection. Late genes are then expressed from 140 min to 48 hours post-infection, producing all structural proteins.
- IMV virion intracellular mature virion
- EEV enveloped virion
- the virus exits the host cell by existing in occlusion bodies after cell death and remains infectious until it finds another host. Replication-competent as well as inactivated Parapoxviruses are known for their immunomodulating properties (Schulze et al., 2009, Vet Microbiol. 137: 260-7).
- Parapoxvirus ovis (ORFV), the prototype species of the parapoxvirus genus, has been used successfully in veterinary medicine for increasing general resistance in animal chronically persistent viral infections (see e.g. US6,365,393; WO97/32029 and US2003/0013076) as well as in human medicine for treating HIV (W02006/005529) and considered as oncolytic (Rintoul et al., 2012, Mol. Ther.20(6): 1148-57).
- ORFV Parapoxvirus ovis
- ORFV canine distemper virus
- W02012/01145 canine distemper virus
- pseudorabies virus in pigs Rost al., 2010, Vaccine 28(7): 1808-13.
- Zylexis® formerly known as Baypamune®, which is a preparation of chemically inactivated ORFV derived from strain D1701 is used for the prophylaxis and therapeutic treatment of infectious diseases and for preventing stress- induced diseases in animals.
- Inactivated ORFV was shown to induce plasmacytoid dendritic cells (pDC) probably through the engagement of a TLR-9 dependent pathway (Von Buttlar et al., 2014, PLOS One 9(8): el06188). More recently, it has been reported potent cytotoxic activities of a chimeric parapoxvirus (referred as CF189) as an oncolytic immunotherapy in triple negative breast cancer (TNBC) tumors (Choi et al. Surgery. 2018 Feb;163(2):336-342). Active replication of the chimeric ORF virus was detected in the tumor tissues 1 week after its injection and natural killer (NK) cell infiltration was observed in the periphery of virus treated tumor tissues.
- NK natural killer
- ORF virus has an effective monotherapy in a murine model of advanced-stage epithelial ovarian cancer, and support the translational potential of ORFV as a NK stimulating immunotherapeutic for treatment of such cancer (Van Vloten et al. J Immunother Cancer 2022;10:e004335). It was also shown that ORFV infection enhances CXCL16 secretion and causes oncolysis of lung cancer cells through immunogenic apoptosis (Wang et al. Front Cell Infect Microbiol. 2022 Jul 25;12:910466).
- PCPV Pseudocowpox virus
- W02019/170820 discloses a Pseudocowpox virus (PCPV) encoding a heterologous nucleic acid inserted in its genome and its therapeutic use for preventing or treating proliferative diseases like cancers (Ramos et al. Clin Transl Immunology. 2022 May 8;ll(5):el392).
- PCPV-infected peripheral blood mononuclear cells induced the secretion of very high levels of IFN-alpha in a MOI-dependent way (MOI: Multiplicity of infection).
- MOI Multiplicity of infection
- the levels secreted by the PCPV- infected PBMC are well above the moderate secretion levels of IFN-alpha observed with Swine pox virus (SWPV) and Parapoxvirus ovis (ORFV).
- SWPV Swine pox virus
- ORFV Parapoxvirus ovis
- PCPV induced a 1000-fold higher expression of IFN-alpha in human PBMCs whereas SWPV and ORFV displayed a lower 10 to 100-fold induction.
- Copenhagen Vaccinia Virus and other oncolytic vectors did not raise the IFN alpha level.
- Parapoxvirus ovis (ORFV) and Yaba-like disease virus (YLDV) were particularly toxic on infected PBMCs: 90% of cells infected at the MOI of 5 died within 16 hours, while at least 50% of living cells were observed for all other viruses, including PCPV.
- PCPV was also shown to be superior to MVA and Vaccinia Virus to trigger the expression of CD86 in primary human monocyte-derived dendritic cells (moDCs).
- PCPV-E7 As a recombinant vector, assessment of immunogenicity was shown in a model of a recombinant PCPV encoding for the non-oncogenic form of the E7 protein (deleted for amino acids 21-26) of human papillomavirus type 16 (HPV16), thereafter referred as PCPV-E7.
- PCPV-E7 vaccinated mice showed a significant increase in the number of E7-specific T cells.
- a significantly higher percentage of antigen-specific CD8+ T cells was observed in the PCPV-E7 group compared to MVA-E7.
- PCPV-E7 as a therapeutic vaccine candidate was also challenged in a translational setting in HPV16+ infected HNSCC (head and neck squamous cell carcinoma) cancer patients, with MVA-E7 vaccine as control.
- HNSCC head and neck squamous cell carcinoma
- MVA-E7 vaccine as control.
- TDLN tumor-draining lymph nodes
- IFN-a is able to induce rapid differentiation of monocytes into highly activated dendritic cells called IFN-DCs, which are particularly effective in inducing B and T cell immunity (Rizza et al. Autoimmunity. 2010 Apr;43(3):204-9).
- the Inventors designed a novel recombinant pseudocowpox virus (PCPV) comprising inserted in its genome at least one heterologous gene encoding for an interleukin 12 (IL-12), and methods of generating and using such recombinant PCPV.
- PCPV pseudocowpox virus
- PCPV recombinant PCPV induced both an upregulation of NK cells (natural killer cells) and an upregulation of activated CD8 T cells (CD8+ T cells) when injected to a patient suffering from a cancer, as it will be further described in the present disclosure.
- the Inventors designed a novel recombinant PCPV comprising inserted in its genome: at least one heterologous gene encoding for an interleukin 12 (IL-12); and at least one heterologous gene encoding for an antigen, preferably a tumor antigen, or a viral antigen.
- IL-12 interleukin 12
- an antigen preferably a tumor antigen, or a viral antigen.
- the Inventors have identified that treatment of a tumor with a recombinant PCPV encoding for an IL-12 and a tumor antigen increased survival of the patient and reduced the tumor growth, and an upregulation of antigen-specific CD8+ T cells, compared to a treatment of a tumor with a recombinant PCPV encoding for the same tumor antigen only (to be understood: without encoding for an IL-12).
- PCPVs described herein are expected to stimulate or improve immune response, especially in cancer immunotherapy.
- the present invention thus relates to a recombinant pseudocowpox virus (PCPV) comprising at least one heterologous nucleic acid inserted in its genome; wherein one of the at least one heterologous nucleic acid inserted in its genome is a nucleic acid encoding for an interleukin 12 (IL-12).
- PCPV pseudocowpox virus
- said PCPV is obtained from the wild-type TJS strain as identified by ATCC reference number ATCC VR-634TM or from a virus strain of the same or similar name or functional fragments and variants thereof.
- said PCPV is further defective for a viral function encoded by the PCPV genome and preferably is defective for a non-essential viral function and, more preferably for a viral gene function encoded at the insertion site of said heterologous nucleic acid.
- said heterologous nucleic acid encodes a polypeptide selected from the group consisting of a suicide gene product; an immunomodulatory polypeptide; an antigenic polypeptide; an antibody; a functional derivative of an antibody; a functional fragment of an antibody; and any combination thereof.
- the immunomodulatory polypeptide is selected from the group consisting of cytokines, such as interleukins, chemokines, interferons, tumor necrosis factor, colony-stimulating factors, polypeptides having an anti-angiogenic effect and agonists or antagonists of immune checkpoints, an any combination thereof.
- cytokines such as interleukins, chemokines, interferons, tumor necrosis factor, colony-stimulating factors, polypeptides having an anti-angiogenic effect and agonists or antagonists of immune checkpoints, an any combination thereof.
- an immunomodulatory polypeptide that is an interleukin or a colony-stimulating factor and, in particular GM-CSF or is an agonist OX40-directed antibody; or the immunomodulatory polypeptide is a tumor necrosis factor, in particular a CD40L, an IL-4, an IL-21 or a BAFF.
- the antigenic polypeptide is a tumor antigen, selected from the group consisting of tumor-associated antigens (TAA), tumor-specific antigens (TSA) and oncoviral antigens.
- TAA tumor-associated antigens
- TSA tumor-specific antigens
- oncoviral antigens said tumor antigen is a class I or class II epitope derived from a tumor antigen, or a combination of class I epitopes, or a combination of class II epitopes, or a combination of class I and class II epitopes.
- said antigenic polypeptide is a full-length antigen.
- the TAA is selected from the group consisting of WT1, MAGE-A3 MUC1, HER2/Neu and NY-ESO-1; or a tissue specific TAA, preferably a tissue specific TAA selected among Mesothelin, PSA, and gplOO.
- the TSA is selected from the group consisting of viral oncogenes; preferably a viral oncogene inducing virus selected among EBV antigens, HPV antigens; or a mutated self TSA, preferably a mutated self TSA selected among EGFRvlll, KRAS, p53 and BRAF; or neo-epitopes resulting from non-synonymous somatic mutations.
- the oncoviral antigens is selected among viral oncogene inducing virus selected among EBV antigens, HPV antigens.
- the at least one heterologous nucleic acid is operably linked to suitable regulatory elements for expression in a desired host cell or subject.
- the at least one heterologous nucleic acid is placed under the control of a poxvirus promoter, preferably, a vaccinia virus promoter and more preferably one selected from the group consisting of the p7.5K, pH5R, pllK7.5, pSE, pTK, pB2R, p28, pll, pF17R, pA14L, pSE/L, pA35R, pCIR and pKIL promoter, synthetic promoters and early/late chimeric promoters.
- a poxvirus promoter preferably, a vaccinia virus promoter and more preferably one selected from the group consisting of the p7.5K, pH5R, pllK7.5, pSE, pTK, pB2R, p28, pll, pF17R, pA14L, pSE/L, pA35R, pCIR and pKIL promoter, synthetic promoters and early/late chimeric promoter
- the at least one heterologous nucleic acid is inserted in the VEGF locus.
- the at least one heterologous nucleic acid inserted in its genome is a nucleic acid encoding for an interleukin 12 (IL-12), wherein the IL-12 is human IL-12.
- IL-12 interleukin 12
- the IL-12 is a fusion protein comprising an IL-12 p40 subunit and an IL-12 p35 subunit.
- the IL-12 p40 subunit is N-terminal to the IL-12 p35 subunit.
- the IL-12 p40 subunit comprises the amino acid sequence of SEQ ID NO:
- amino acid sequence 1 or an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the amino acid sequence of SEQ. ID NO: 1.
- the IL-12 p35 subunit comprises the amino acid sequence of SEQ ID NO:
- the IL-12 p40 subunit and the IL-12 p35 subunit are fused in a single polypeptide via an amino acid linker.
- said amino acid linker is about 5 to about 10 amino acids in length.
- said amino acid linker is 7 amino acids in length.
- the amino acid linker is a glycine-serine linker.
- the amino acid linker comprises the amino acid sequence of SEQ ID NO: 3.
- the IL-12 comprises the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% identical to the amino acid sequence of SEQ ID NO: 4.
- the IL-12 p40 subunit and the IL-12 p35 subunit are directly fused in a single polypeptide.
- the nucleic acid sequence encoding the IL-12 comprises a nucleotide sequence at least 75% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, at least 96% identical, at least 97% identical, at least 98% identical, or at least 99% identical to the nucleotide sequence of SEQ ID NO: 5.
- the nucleic acid sequence encoding the IL-12 comprises the nucleotide sequence of SEQ ID NO: 5.
- the nucleic acid sequence encoding the IL-12 is inserted within the VEGF locus.
- the nucleic acid sequence encoding the IL-12 is inserted within the VEGF locus; and said PCPV further comprises a heterologous nucleic acid encoding for an antigenic polypeptide which is also inserted within the VEGF locus.
- the expression cassette comprising the nucleic acid sequence encoding the IL-12 and the expression cassette comprising the nucleic acid encoding the antigenic polypeptide are in a back-to-back orientation in relation to each other within the VEGF locus.
- the nucleic acid sequence encoding the IL-12 is placed under control of a pSE/L promoter, and the nucleic acid encoding the antigenic polypeptide is placed under control of a p7.5K promoter.
- the present invention further provides a method for generating the PCPV of the invention, by homologous recombination between a transfer plasmid comprising the heterologous nucleic acid flanked in 5' and 3' with PCPV sequences respectively present upstream and downstream the insertion site and a PCPV genome, wherein said method comprises a step of generating said transfer plasmid and a step of introducing said transfer plasmid into a suitable host cell, notably together with a PCPV virus comprising the flanking sequence present in the transfer plasmid.
- the site of insertion of the at least one heterologous nucleic acid in the PCPV genome is in a viral gene, with a preference for a non-essential viral gene, in an intergenic region, in a portion of the PCPV genome which does not encode gene products or in a duplicated locus.
- the method for generating the PCPV comprises a step wherein upon insertion of the heterologous nucleic acid in the PCPV genome the viral locus at the insertion site is deleted at least partially, resulting in a defective PCPV virus for said virus function.
- said at least one heterologous nucleic acid is inserted in the VEGF locus.
- the transfer plasmid further comprises one or more selection and/or detectable gene to facilitate identification of the recombinant PCPV.
- the transfer plasmid is introduced into the host cell in the presence of an endonuclease capable of providing a double-stranded break in said selection or detectable gene.
- the selection gene used in the method for generating the PCPV is the GPT gene encoding a guanine phosphoribosyl transferase permitting growth in a selective medium and/or said detectable gene encodes GFP, e-GFP or mCherry.
- the suitable host cell is selected from Bovine Turbinate (BT) cell or HeLa cell.
- the present invention further provides a method for amplifying the PCPV according to the invention, or generated by the method according to the invention, comprising the steps of a) preparing a producer cell line, b) transfecting or infecting the prepared producer cell line, c) culturing the transfected or infected producer cell line under suitable conditions so as to allow the production of the virus, d) recovering the produced virus from the culture of said producer cell line and optionally e) purifying said recovered virus.
- the producer cell is Bovine Turbinate (BT) or HeLa.
- the present invention further provides a composition comprising a therapeutically effective amount of the PCPV according to the present disclosure, or amplified by the method according to the present disclosure, and a pharmaceutically acceptable vehicle.
- the composition is thus preferably a pharmaceutical composition.
- said composition is formulated in individual doses comprising from approximately 10 3 to approximately 10 12 pfu, advantageously from approximately 10 4 pfu to approximately 10 11 pfu, preferably from approximately 10 5 pfu to approximately IO 10 pfu; and more preferably from approximately 10 s pfu to approximately 10 9 pfu of PCPV.
- composition is formulated for intravenous, intramuscular, intradermal, intranasal, subcutaneous or intratumoral administration.
- said composition is for use for treating or preventing diseases or pathological condition caused by a pathogenic organism or an unwanted cell division, or for inhibiting tumor cell growth.
- composition according to the invention for the manufacture of a drug for treating or preventing diseases or pathological condition caused by a pathogenic organism or an unwanted cell division, or for inhibiting tumor cell growth.
- composition according to the invention for treating or preventing diseases or pathological condition caused by a pathogenic organism or an unwanted cell division, or for inhibiting tumor cell growth.
- composition according to the invention comprising administering the composition according to the invention to a subject in need thereof in an amount sufficient to treat or prevent a disease or a pathological condition caused by a pathogenic organism or an unwanted cell division. It is also disclosed a method for inhibiting tumor cell growth comprising administering the composition of the present invention to a subject in need thereof.
- composition for use, the use or the method according to the present disclosure comprising 2 to 6 weekly administrations possibly followed by 2 to 15 administrations at 3 weeks interval of the PCPV composition comprising 10 s to 10 9 pfu.
- composition for use, the use or the method according to the present invention wherein said method or use is for treating a cancer selected from the group consisting of renal cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, lung cancer, liver cancer, gastric cancer, bile duct carcinoma, endometrial cancer, pancreatic cancer, ovarian cancer, head and neck cancer, melanoma, glioblastoma, multiple myeloma, or malignant glioma cells.
- a cancer selected from the group consisting of renal cancer, prostate cancer, breast cancer, bladder cancer, colorectal cancer, lung cancer, liver cancer, gastric cancer, bile duct carcinoma, endometrial cancer, pancreatic cancer, ovarian cancer, head and neck cancer, melanoma, glioblastoma, multiple myeloma, or malignant glioma cells.
- composition for use, the use or the method according to the present invention which is used in conjunction with one or more other therapeutic agents selected from the group consisting of surgery, radiotherapy, chemotherapy, cryotherapy, hormonal therapy, toxin therapy, immunotherapy, cytokine therapy, targeted cancer therapy, gene therapy, photodynamic therapy and transplantation.
- composition for use, the use or the method according to the present invention which is carried out according to a prime boost approach which comprises sequential administrations of a priming composition(s) and a boosting composition(s).
- composition for use, the use or the method according to the invention wherein the priming composition is a PCPV composition, and the boosting composition is a MVA composition or a PCPV composition.
- composition for use, the use or the method according to the present disclosure whereas the priming composition is a PCPV composition administered by intratumoral route and the boosting composition is a MVA composition administered by intravenous route.
- composition according to the invention is for use for eliciting or stimulating and/or re-orienting an immune response in a subject in need thereof.
- composition according to the invention for the manufacture of a drug for eliciting or stimulating and/or re-orienting an immune response in a subject in need thereof.
- composition according to the invention for eliciting or stimulating and/or re-orienting an immune response in a subject in need thereof.
- composition according to the present invention preferably results in at least one the following properties:
- FIG. 1 IFN-a and IL12-p70 secretion by PBMCs from cancer patients. IFN-a secretion in PBMC cultures from 10 cancer patients. The patients, between 31 and 78 years of age, had different indications (breast, lung, bladder, and head and neck cancer) and were untreated when blood was drawn. PBMCs were infected at MOI 0.3 with PCPV-GFP, MVA-GFP or VACV-GFP. IFN-a and IL12p70 secretion was measured in the cell culture supernatant the next day. Shown is the mean IFN-a and IL12p70 secretion in 10 individuals +/- SEM.
- FIG. 1 Schematic representation of recombinant PCVPs according to the invention.
- FIG. 1 A) Western Blot analysis: detection of epitope expression with anti-Flag HRP (horse radish peroxidase) antibody.
- PCPTG19873 shows around 5-fold higher gene expression than PCPTG19874
- FIG. 4 Murine splenocytes were infected at MOI 0.3 and 1 with PCPV-mlL12 (filled triangle; code number PCPTG19818) or PCPV-ctr (filled quadrangle) or remained uninfected (empty circle). Next day, supernatant was harvested, and IFN-gamma determined by Luminex analysis. Splenocytes were stained with antibodies and Live Dead before being analyzed on a MacsQuant cytometer. Gating strategies using the Kaluza 2.1.1 software (Beckman Coulter): SSC vs FSC. Dot plot (LiveDead vs SSC) to determine live cells.
- Dot plots of live cells were created to identify the CD3+CD8+, CD3+CD4+ or the NK cells CD49b+CD3-. From each of these populations, dot plots CD69 vs PDL1 were created to phenotype the activation state of these lymphocytes. Double positive populations were shown. A representative experiment is shown.
- PBMCs were infected at MOI 0.3 with PCPV-mlL12 (code number PCPTG19818) or a control PCPV (PCPV-ctr). Next day, supernatant was harvested, and IFN-gamma determined by Luminex analysis. Cells were stained with antibodies and Live Dead before being analyzed on a MacsQuant cytometer. Gating strategies using the Kaluza 2.1.1 software (Beckman Coulter): SSC vs FSC. Dot plot (LiveDead vs SSC) to determine live cells. Dot plots of live cells were created to identify the CD3+CD8+, CD3+CD4+ or the NK cells CD56+CD3-. From each of these populations, dot plots with CD69 vs PDL1 were created to phenotype the activation state of these lymphocytes. Double positive populations were shown. A representative experiment is shown.
- PCPV-mlL12 (code number PCPTG19818) controls tumor growth better than PCPV-ctr and increases survival frequencies:
- FIG. 7 Nine days after MC38 tumor cell grafting, 5xl0 5 pfu of PCPV-ctr, PCPV-mlL12 or the empty MVA vector MVA-ctr were injected into the growing tumors (5 mice per group). The day after, mice were sacrificed, axillary and inguinal draining lymph nodes (DLN) were harvested and analyzed by flow cytometry. Shown are the mean frequencies of activated NK cells, and activated CD8+ and CD4+ T cells in 5 individuals +/- SEM.
- FIG. 8 Naive C57BL/6 mice were repeatedly (days 0, 7 and 14) vaccinated (sc) with lxlO 7 pfu of PCPV-ctr, PCPTG19873or PCPTG19874. Blood was taken at days 7, 14 and 45 (10 mice per group). SlINFEKL-specific T cells were identified by flow cytometry using SlINFEKL-pentamer staining. The day after, mice were sacrificed, axillary and inguinal draining lymph nodes (DLN) were harvested and analyzed by flow cytometry. Shown are the mean frequencies of SlINFEKL-specific CD8+ T cells in 10 individuals +/- SEM. Figure 9.
- FIG. 10 Detection of murine IL12 in extracellular vesicle (EV) fraction isolated from infected PBMCs: Suspensions of PCPV-mlL12, incubated o/n with or without PBMCs at MOI 1, were cleared by centrifugation, concentrated, filtered, and ultracentrifuged. mlL12 was quantified after concentration and in EV fraction by Luminex analysis.
- EV extracellular vesicle
- SP is a signal peptide from the rabies glycoprotein: amino acid 1-23 (P32550.1)
- Msln is an epitope from Mus musculus Mesothelin: amino acid 396-424 (NP_001343215)
- SIINFEKL is a reference for an amino acid sequence known as a pure CD8 epitope
- ISQAVHAAHAEINEAGR is a reference for an amino acid sequence known as a pure a pure CD4 epitope
- CB100 is an epitope from Pyrophorus plagiophtalamus luciferase: amino acid 91-119 (Uniprot S29353)
- CB441 is an epitope from Pyrophorus plagiophtalamus luciferase: amino acid 430-458 (Uniprot S29353)
- Flag is a FLAG tag (Flag HRP (horse radish peroxidase))
- DMSO Dimethyl sulfoxide
- KNGENAQAI referenced as CTRL on Figure 12
- Figure 14 Figure 14 ( Figure 14A and Figure 14B). Comparison of tumor growth PCPV-OVA-IL12 (PCPTG19874), PCPV-OVA (PCPTG19873), MVA-OVA-IL-12 (MVATG20014) and MVA-OVA (MVATG20022) versus their respective control vectors PCPV ctr and MVA ctr in E.G7-OVA tumor model.
- Figure 14A Measured tumor volume in mm 3
- Figure 14B Graphical representation of an estimated tumor diameter expressed in mm 2 based on mixed model built with measured tumor volume according to Figure 15a and accorded to the method described in Bastogne et al, 2010.
- a recombinant pseudocowpox virus comprising at least one heterologous nucleic acid inserted in its genome, wherein one of the at least one heterologous nucleic acid inserted in its genome is a nucleic acid encoding for an interleukin 12 (IL-12), induced an improve immune response.
- PCPV pseudocowpox virus
- IL-12 interleukin 12
- the vectorization of IL-12 into PCPV is therefore a solution to such problem of a vaccination approach for minimizing toxicities and providing antitumor efficacy.
- the recombinant PCPV according to the invention showed interesting capacity to produce secreted IL-12 within extracellular vesicles (EVs). It is known in the art that exosome therapeutic that displays functional IL-12 exhibit prolonged tumor retention and greater antitumor activity than a recombinant IL-12 (Lewis et al. Mol Cancer Ther. 2021 Mar;20(3):523-534). Such prolonged retention could increase the effects of IL-12 on tumor-resident NK and T cells, leading to their activation or reinvigoration.
- a and “an” are used in the sense that they mean “at least one”, “at least a first”, “one or more” or “one or a plurality” of the referenced compounds or steps, unless the context dictates otherwise.
- a cell includes a plurality of cells, including mixtures thereof.
- one or more refers to either one or a number above one (e.g. 2, 3, 4, etc.).
- amino acids amino acids
- amino acid analogs e.g. non-natural, synthetic and modified amino acids, including D or L optical isomers.
- a polypeptide “comprises” an amino acid sequence when the amino acid sequence might be part of the final amino acid sequence of the polypeptide.
- Such a polypeptide can have up to several hundred additional amino acids residues (e.g.
- polypeptide refers to polymers of amino acid residues comprising at least nine amino acids covalently linked by peptide bonds.
- the polymer can be linear, branched or cyclic and may comprise naturally occurring and/or amino acid analogs and it may be interrupted by non-amino acids. No limitation is placed on the maximum number of amino acids comprised in a polypeptide. As a general indication, the term refers to both short polymers (typically designated in the art as peptide) and to longer polymers (typically designated in the art as polypeptide or protein).
- This term encompasses native polypeptides, modified polypeptides (also designated derivatives, analogs, variants or mutants), polypeptide fragments, polypeptide multimers (e.g. dimers), recombinant polypeptides, fusion polypeptides among others.
- nucleic acid refers to any polymer of at least 9 nucleotide residues in either deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) or mixed polyribo-polydeoxyribonucleotides.
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- mixed polyribo-polydeoxyribonucleotides encompass single or double-stranded, linear or circular, natural or synthetic, unmodified or modified versions thereof (e.g. genetically modified polynucleotides; optimized polynucleotides), sense or antisense polynucleotides, chimeric mixture (e.g.
- RNA-DNA hybrids include without limitation, complementary DNA (cDNA), genomic DNA, plasmid DNA, vectors, viral DNA (e.g. viral genomes, viral vectors), oligonucleotides, probes, primers, coding DNA, non-coding DNA, or any fragment thereof etc.
- exemplary RNA nucleic acids include, without limitation, messenger RNA (mRNA), precursor messenger RNA (pre-mRNA), coding RNA, non-coding RNA, etc.
- Nucleic acid sequences described herein may be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as those that are commercially available from Biosearch, Applied Biosystems, etc.) or obtained from a naturally occurring source (e.g. a genome, cDNA, etc.) or an artificial source (such as a commercially available library, a plasmid, etc.) using molecular biology techniques well known in the art (e.g. cloning, PCR, etc).
- an automated DNA synthesizer such as those that are commercially available from Biosearch, Applied Biosystems, etc.
- a naturally occurring source e.g. a genome, cDNA, etc.
- an artificial source such as a commercially available library, a plasmid, etc.
- the percent identities referred to in the context of the disclosure of the present invention are determined after optimal global alignment of the sequences to be compared, which optimal global alignment may therefore comprise one or more insertions, deletions, truncations and/or substitutions.
- the alignment is global, meaning that it includes the sequences to be compared taken in their entirety over their entire length.
- the alignment is "optimal", meaning that the number of insertions, deletions, truncations and/or substitutions is made as low as possible.
- the optimal global alignment may be performed and the percent identity calculated using any sequence analysis method well-known to the person skilled in the art. In addition to manual comparison, it is possible to determine global alignment using the algorithm of Needleman and Wunsch (1970).
- the sequence comparison may be performed using any software well-known to a person skilled in the art, such as the Needle software.
- the parameters used may notably be the following: “Gap open” equal to 10.0, “Gap extend” equal to 0.5, and the EDNAFULL matrix (NCBI EMBOSS Version NUC4.4).
- the sequence comparison may be performed using any software well-known to a person skilled in the art, such as the Needle software.
- the parameters used may notably be the following: “Gap open” equal to 10.0, “Gap extend” equal to 0.5, and the BLOSUM62 matrix.
- variants can be used interchangeably to refer to a component (polypeptide, nucleic acid, virus, etc) exhibiting one or more modification(s) with respect to the native counterpart. Any modification(s) can be envisaged, including substitution, insertion and/or deletion of one or more nucleotide/amino acid residue(s).
- variants that retain a degree of sequence identity of at least 75%, advantageously at least 80%, desirably at least 85%, preferably at least 90%, more preferably at least 95%, and even more preferably at least 98% identity after optimal global alignment with the sequence of the native counterpart, i.e.
- identity means 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%.
- identity refers to an amino acid to amino acid or nucleotide to nucleotide correspondence between two polypeptides or nucleic acid sequences.
- the percentage of identity between two sequences is a function of the number of identical positions shared by the sequences, considering the number of gaps which need to be introduced for optimal alignment and the length of each gap.
- Various computer programs and mathematical algorithms are available in the art to determine the percentage of identity between amino acid sequences, such as for example the Blast program available at NCBI or ALIGN in Atlas of Protein Sequence and Structure (Dayhoffed, 1981, Suppl., 3: 482-9).
- Emboss Needle software available at https://www.ebi.ac.uk/Tools/psa/emboss_needle/.
- This software reads two input sequences and writes their optimal global sequence alignment to file. It uses the Needleman-Wunsch alignment algorithm to find the optimum alignment (including gaps) of two sequences along their entire length. The algorithm uses a dynamic programming method to ensure the alignment is optimum, by exploring all possible alignments and choosing the best. A scoring matrix is read that contains values for every possible residue or nucleotide match.
- Needle finds the alignment with the maximum possible score where the score of an alignment is equal to the sum of the matches taken from the scoring matrix, minus penalties arising from opening and extending gaps in the aligned sequences.
- the substitution matrix and gap opening and extension penalties are user-specified.
- the Emboss Needle software may be used with default parameters, i.e. :
- originating or “originate” is used to identify the original source of a component (e.g. polypeptide, nucleic acid molecule) but is not meant to limit the method by which the component is made which can be, for example, by chemical synthesis or recombinant means.
- a component e.g. polypeptide, nucleic acid molecule
- the term "host cell” should be understood broadly without any limitation concerning particular organization in tissue, organ, or isolated cells. Such cells may be of a unique type of cells or a group of different types of cells such as cultured cell lines, primary cells and dividing cells. This term also includes cells that can be or has been the recipient of the non-propagative viral vector for use in the invention, as well as progeny of such cells.
- subject generally refers to a vertebrate organism for whom any of the product or methods disclosed herein is needed or may be beneficial.
- the organism is a mammal, particularly a mammal selected from the group consisting of domestic animals, farm animals, sport animals, and primates (human and non-human).
- subject and patient may be used interchangeably when referring to a human organism and covers male and female as well as a fetuses, newborn, infant, young adult, adult and elderly.
- tumor may be used interchangeably with any of the terms “cancer”, “malignancy”, “neoplasm” and encompasses any disease or pathological condition resulting from uncontrolled cell growth and spread. These terms are meant to include any type of tissue, organ or cell, any stage of malignancy (e.g. from a prelesion to stage IV). Typically, tumors, especially malignant tumors, show partial or complete lack of structural organization and functional coordination as compared to normal tissue and generally show a propensity to invade surrounding tissues (spreading) and/or metastasize to farther sites.
- the present invention is preferably designed for the treatment of solid tumors as described herein.
- a “neoplastic cell”, “cancer cell” or “tumor cell” can be used interchangeably to refer to a cell that divides at an abnormal (i.e. increased) rate.
- treatment refers to therapy.
- therapy refers to a pathological condition with the purpose to improve at least one clinical or biochemical symptom (size of tumor, expression level of associated biomarker%), to slow down or control the progression of the targeted pathological condition, symptom(s) thereof, or a state secondary to the pathological condition in the subject treated in accordance with the present invention.
- prevention and any form of the term such as “preventing”, “prevent”, etc.,) and “prophylaxis” are used interchangeably and refer to preventing, delaying the onset or decreasing the severity of the first occurrence or relapse of at least one clinical or biochemical symptom (size of tumor, expression level of associated biomarker, stage progression).
- administering refers to the delivery to a subject of a component (e.g. the fusion polypeptide according to the invention) according to the modalities described herein.
- fusion polypeptide refers to any arrangement possible of various components (e.g. the fusion polypeptide according to the invention and another treatment). Such an arrangement includes mixture of said components as well as separate combinations for concomitant or sequential administrations.
- the present invention encompasses combinations comprising equal molar concentrations of each component as well as combinations with very different concentrations. It is appreciated that optimal concentration of each component of the combination can be determined by the artisan skilled in the art.
- virus refers to viral particles that are formed when the nucleic acid vector is transduced into an appropriate cell or cell line according to suitable conditions allowing the generation of viral particles.
- viral vector has to be understood broadly as including nucleic acid vector (e.g. DNA viral vector) as well as viral particles generated thereof.
- infectious refers to the ability of a viral vector to infect and enter into a host cell or subject.
- Viral vectors can be replication-competent or -selective (e.g. engineered to replicate better or selectively in specific host cells), or can be genetically disabled so as to be replicationdefective or replication-impaired.
- viral vector refers to a nucleic acid vector that includes at least one element of a virus genome and may be packaged into a viral particle or to a viral particle.
- Naturally occurring is used to describe a biological molecule or organism that can be found in nature as distinct from being artificially produced by man.
- a naturally occurring, native or wild-type virus refers to a virus which can be isolated from a source in nature or obtained from specific collections (e.g. ECCAC, ATCC, CNCM, etc).
- a biological molecule or an organism which has been intentionally modified by man in the laboratory is not naturally occurring.
- Representative examples of non- naturally occurring viruses include, among many others, recombinant viruses engineered by insertion of one or more nucleic acid(s) of interest in the viral genome and/or defective virus resulting from one or more modification(s) in the viral genome (e.g. total or partial deletion of a viral gene).
- recombinant indicates that the virus has been modified by the introduction of at least one foreign nucleic acid (also called recombinant gene or nucleic acid, or heterologous gene or heterologous nucleic acid), notably a nucleic acid of therapeutic interest as described herein.
- the "heterologous nucleic acid” that is inserted in the PCPV genome is not found in or expressed by a naturally occurring PCPV genome. Nevertheless, the heterologous nucleic acid can be homologous or heterologous to the subject into which the recombinant PCPV is introduced. More specifically, it can be of human origin or not (e.g.
- said heterologous nucleic acid encodes a polypeptide or is a nucleic acid sequence capable of binding at least partially (by hybridization) to a complementary cellular nucleic acid (e.g., DNA, RNA, miRNA) present in a diseased cell with the aim of inhibiting a gene involved in said disease.
- a polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not, and includes peptides and proteins.
- Such a foreign nucleic acid may be a native gene or portion(s) thereof (e.g.
- the heterologous nucleic acid encodes a polypeptide which is capable of providing a therapeutic or prophylactic activity when administered appropriately to a subject (i.e. a polypeptide of therapeutic interest), leading to a beneficial effect on the course or a symptom of the pathological condition to be treated.
- a polypeptide of therapeutic interest i.e. a polypeptide of therapeutic interest
- the heterologous nucleic acid encodes a polypeptide selected from the group consisting of polypeptides that compensate for defective or deficient proteins in a subject, polypeptides that act through toxic effects to limit or remove diseased cells from the body (e.g.
- suicide gene products polypeptides capable of potentiating anti-tumor efficacy (e.g. armed gene products); and polypeptides capable of inducing or activating an immune response (such as immunomodulatory and antigenic polypeptides).
- a heterologous nucleic acid encoding a detectable gene product may also be useful in the context of the invention.
- immunomodulatory polypeptide is used to describe a polypeptide capable of modifying or regulating one or more immune functions (up or downregulation).
- tumor antigen or "tumoral antigen”, or “tumoral specific antigen” is used to describe a protein of peptide that can be recognized by cellular or humoral components of the immune system to target tumor tissue.
- Tumor is to be understood as abnormal neoplastic tissular formations that might have or not a malignant behaviour.
- a malignant behaviour is usual associated with spreading and invasion of the nearby tissue and throughout the body. Malignancy is associated with cancer and many non-malignant tumors have the potential to evolve toward a malignant tumor.
- the antigen can be a full-length antigen, or an epitope derived from an antigen or an association of epitopes, an epitope being defined as the shortest sequence from an antigen necessary and sufficient to induce a class I or a class II response.
- TAA tumor-associated antigens
- TSA tumor-specific antigens
- antibody is used in the broadest sense and encompasses naturally occurring antibodies and engineered antibodies; including synthetic, monoclonal, polyclonal antibodies as well as full length antibodies and fragments, variants or fusions thereof provided that such fragments, variants or fusions retain binding properties to the target protein.
- Such antibodies can be of any origin; human or non-human mammal (e.g. rodent or camelid antibody), or chimeric.
- a nonhuman antibody can be humanized by recombinant methods to reduce its immunogenicity in human.
- the antibody may derive from any of the well-known isotypes (e.g.
- antibody also includes an antigen-binding fragment of any of the aforementioned antibodies and includes a monovalent and a divalent fragment and single chain antibodies.
- the term antibody also includes multi-specific (e.g. bispecific) antibody so long as it exhibits the same binding specificity as the parental antibody. It is within the skill of the artisan to screen for the binding properties of a candidate antibody.
- full length antibodies are glycoproteins comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
- Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region which is made of three CHI, CH2 and CH3 domains (optionally with a hinge between CHI and CH2).
- Each light chain comprises a light chain variable region (VL) and a light chain constant region which comprises one CL domain.
- the VH and VL regions comprise three hypervariable regions, named complementarity determining regions (CDR), interspersed with four conserved regions named framework regions (FR) in the following order: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
- a "humanized antibody” refers to a nonhuman (e.g. murine, camel, rat, etc) antibody whose protein sequence has been modified to increase its similarity to a human antibody (i.e. produced naturally in humans).
- the process of humanization is well known in the art and typically is carried out by substituting one or more residue of the FR regions to look like human immunoglobulin sequence whereas the vast majority of the residues of the variable regions (especially the CDRs) are not modified and correspond to those of a non-human immunoglobulin.
- a “chimeric antibody” comprises one or more element(s) of one species and one or more element(s) of another species, for example, a non-human antibody comprising at least a portion of a constant region (Fc) of a human immunoglobulin.
- the antibody is preferably a monoclonal antibody, preferably humanized or chimeric.
- antibody fragments and/or regions are known in the art, including heavy (H) chain, light (L), heavy chain variable region (VH), heavy chain constant region, CH domain, light chain variable region (VL), light chain constant region, CL domain, complementarity determining regions (CDR), constant region (Fc), Fab, Fab', F(ab')2, dAb, Fd, Fv, scFv, ds-scFv, diabody, sdAb, etc.
- antigen-binding fragments include Fab, Fab', F(ab')2, dAb, Fd, Fv, scFv, ds-scFv, and diabody.
- a particularly useful antibody fragment is a single chain antibody (scFv) comprising the two domains of a Fv fragment, VL and VH, that are fused together, eventually with a linker to make a single protein chain.
- APC antigen presenting cell
- APC antigen presenting cell
- APC-exposed proteins any antigenic protein displayed by an APC on its surface and that may be presented to T-cells in order to trigger an adaptative immune response.
- PCPV pseudocowpox virus
- Pseudocowpox virus is a virus of the genus Parapoxvirus that causes pseudocowpox in humans and cattle.
- Pseudocowpox occurs as a common enzootic infection of cattle in most countries of the world. The infection is most frequent in milking herds, affecting the teats and udder of cows and the muzzles and mouths of nursing calves.
- the lesions of pseudocowpox are characterized by "ring" or "horseshoe"-shaped scabs, the latter being characteristic of the disease. Infection is transmitted by cross-suckling of calves, improperly disinfected teat clusters of milking machines, and probably by the mechanical transfer of virus by flies.
- PCPV possesses a linear and double-stranded DNA genome, typically of 130-150 kilobases.
- the present invention encompasses naturally occurring forms of pseudocowpox virus of any strain as well as variants thereof which may be modified for various purposes including those described herein.
- PCPV strains for use herein include, without limitation, YG2828 (Genbank accession number LC230119), F07.801 R (Genbank accession number JF773693), F10.3081C (Genbank accession number JF773695), F07.798R (Genbank accession number JF773692), F99.177C (Genbank accession number AY453678), IT1303/05 (Genbank accession number JF800906), F00.120R (Genbank accession number GQ329669; Tikkanen et al., 2004, J. Gen. Virol.
- TJS also called VR634; Genbank accession number GQ.329670; Friedman- Kien et al., 1963, Science 140: 1335-6; available at ATCC under accession number VR634).
- Such strains may have morphological, structural and/or genetic differences each other, e.g., in terms of ITR length, number of predicted genes and/or G C rich content (see e.g. Hautaniemi et al., 2010, J. Gen. Virol.91 : 1560-76).
- the PCPV virus of the present invention is obtained from the wild-type TJS strain as identified by ATCC reference number ATCC VR-634TM or from a virus strain of the same or similar name and functional fragments and variants thereof.
- a variant maintains at least 75% identity at the nucleotide or amino acid level with at least a segment of 10 kilobase (e.g. a continuous sequence of lOkb) in the wild-type TJS pseudocowpox virus genome.
- Exemplary modifications that are appropriate in the context of the present invention include without any limitation insertion(s), substitution(s) and/or deletion(s) of one or more nucleotide(s) within the PCPV genome with the goal of modulating (e.g. increase or decrease) expression of one or more viral gene or virus infectivity when compared to the wild-type pseudocowpox virus (e.g. TJS strain) or increasing its therapeutic efficacy (e.g. increase the ability of the PCPV virus to differentially express in diseased cells relative to healthy cells) or insertion of one or more foreign nucleic acid(s) of therapeutic interest or generating a chimeric virus containing PCPV genomic fragment(s) with ones obtained from a different virus origin.
- modulating e.g. increase or decrease expression of one or more viral gene or virus infectivity when compared to the wild-type pseudocowpox virus (e.g. TJS strain) or increasing its therapeutic efficacy (e.g. increase the ability of the PCPV virus to differential
- the PCPV of the invention comprises inserted in its genome at least one foreign nucleic acid (e.g. resulting in a recombinant PCPV virus), wherein one of the at least one heterologous nucleic acid inserted in its genome is a nucleic acid encoding for an interleukin 12 (IL-12).
- IL-12 interleukin 12
- the PCPV virus may be defective for a viral function encoded by the PCPV genome (e.g. a non-essential viral function), preferably for a viral gene function encoded at the insertion site(s) of the foreign nucleic acid.
- a viral function encoded by the PCPV genome e.g. a non-essential viral function
- a viral gene function encoded at the insertion site(s) of the foreign nucleic acid e.g. a non-essential viral function
- PCPV pseudocowpox virus
- recombinant indicates that the virus has been modified by the introduction of at least one foreign nucleic acid (also called recombinant gene or nucleic acid), notably a nucleic acid of therapeutic interest as described herein.
- the "foreign nucleic acid” that is inserted in the PCPV genome is not found in or expressed by a naturally-occurring PCPV genome.
- the foreign nucleic acid can be homologous or heterologous to the subject into which the recombinant PCPV is introduced. More specifically, it can be of human origin or not (e.g. of bacterial, yeast or viral origin except PCPV).
- said foreign nucleic acid encodes a polypeptide or is a nucleic acid sequence capable of binding at least partially (by hybridization) to a complementary cellular nucleic acid (e.g., DNA, RNA, miRNA) present in a diseased cell with the aim of inhibiting a gene involved in said disease.
- a polypeptide is understood to be any translational product of a polynucleotide regardless of size, and whether glycosylated or not, and includes peptides and proteins.
- Such a foreign nucleic acid may be a native gene or portion(s) thereof (e.g. cDNA), or any variant thereof obtained by mutation, deletion, substitution and/or addition of one or more nucleotides.
- the foreign nucleic acid encodes a polypeptide which is capable of providing a therapeutic or prophylactic activity when administered appropriately to a subject (i.e. a polypeptide of therapeutic interest), leading to a beneficial effect on the course or a symptom of the pathological condition to be treated.
- a polypeptide of therapeutic interest may be envisaged.
- the foreign nucleic acid encodes a polypeptide selected from the group consisting of polypeptides that compensate for defective or deficient proteins in a subject, polypeptides that act through toxic effects to limit or remove diseased cells from the body (e.g. suicide gene products); polypeptides capable of potentiating anti-tumor efficacy (e.g. armed gene products); and polypeptides capable of inducing or activating an immune response (such as immunostimulatory and antigenic polypeptides).
- a foreign nucleic acid encoding a detectable gene product may also be useful in the context of the invention.
- PCPV pseudocowpox virus
- Interleukin-12 has been considered as a potential candidate for anti-cancer therapy and has been introduced into viral vectors such as adenoviral vectors for evaluation.
- IL-12 is a cytokine with immune-modulating and anti-angiogenic functions.
- IL-12 acts as a key regulator of cell-mediated immune responses through the induction of T helper 1 differentiation, and it induces cellular immunity by promoting IFN-y production, proliferation, and cytolytic activity of natural killer and T cells.
- the multi-functionality of IL-12 has led to investigation of this cytokine as an anti-cancer agent (Manetti et al. J Exp Med. 1993 Apr l;177(4):1199-204).
- the human IL-12 encoded into the recombinant PCPV is a fusion protein as a single chain IL-12 protein expressed from PCPV in which the full length p40 subunit was fused, via a G6S linker, to the p35 subunit truncated of its leader sequence (Lieschke et al. Nat Biotechnol. 1997 Jan;15(l):35-40). It is to be understood that such embodiment has a purpose of being an illustrative nucleotide sequence encoding an IL-12 and not to be considered as a limiting embodiment of the present invention.
- PCPV pseudocowpox virus
- the recombinant pseudocowpox virus comprising at least one heterologous nucleic acid inserted in its genome; wherein one of the at least one heterologous nucleic acid inserted in its genome is a nucleic acid encoding for an interleukin 12 (IL-12); and wherein one of the at least one heterologous nucleic acid inserted in its genome is a nucleic acid encoding for an antigenic polypeptide which is a tumor antigen.
- PCPV pseudocowpox virus
- Said tumor antigen may be selected from the group consisting of tumor-associated antigens (TAA), tumor-specific antigens (TSA) and oncoviral antigens.
- TAA tumor-associated antigens
- TSA tumor-specific antigens
- Said tumor antigen may be selected from the group consisting of tumor-associated antigens (TAA), tumor-specific antigens (TSA) and oncoviral antigens.
- PCPTG19873 is a PCPV expressing five epitopes (see Figure 11), among them one sequence known to be a pure CD8 OVA epitope of amino acid sequence [SIINFEKL] and CD4 OVA epitope one sequence known to be a pure CD4 epitope of amino acid sequence [ISQAVHAAHAEINEAGR], Epitopes are separated by GSG linkers, the polyepitopes are preceded by a signal peptide for the endoplasmic reticulum (ER) and terminated by a subsequent FLAG tag (Flag HRP (horse radish peroxidase)).
- Said polyepitopes encoded into PCPV is of nucleotide sequence as disclosed as SEQ ID NO: 9.
- the polyepitopes expressed amino acid sequence is disclosed as SEQ. ID NO: 8.
- the expression cassette is under control of the poxviral promoter p7.5K (SEQ ID NO: 7) and inserted in the VEGF loci.
- PCPTG19818 is a PCPV expressing a murine IL-12 (mlL-12) of nucleotide sequence disclosed as SEQ ID NO: 11 under the control of the pSE/L promoter (SEQ ID NO: 6) and inserted in the VEGF loci.
- the mlL-12 amino acid sequence as expressed is disclosed as SEQ ID NO: 10.
- PCPTG19874 is a PCPV expressing a murine IL-12 (mlL-12) of nucleotide sequence disclosed as SEQ ID NO: 11 under the control of the pSE/L promoter (SEQ ID NO: 6) and inserted in the VEGF loci.
- PCPTG19874 is also expressing the same five epitopes (polyepitopes) as PCPTG19873.
- Said polyepitopes encoded into PCPV is of nucleotide sequence as disclosed as SEQ ID NO: 9.
- the polyepitopes expressed amino acid sequence is disclosed as SEQ ID NO: 8.
- the mlL-12 expression cassette and the five epitopes (polyepitopes) expression cassette are inserted into the PCPV genome in a back-to-back orientation in relation to each other, each under separate regulatory control (see Figure 2).
- the expression cassette of the polyepitopes is under control of the poxviral promoter p7.5K (SEQ ID NO: 7).
- the expression cassette of the mlL-12 is under control of the pSE/L promoter (SEQ ID NO: 6).
- MVATG20022 is a MVA expressing four epitopes fused to the C-terminal part of the protein coding for the eGFP. Two epitopes were issued from OVA, one sequence known to be pure CD8 OVA epitope of amino acid sequence [SIINFEKL] and one CD4 OVA epitope of amino acid sequence [ISQAVHAAHAEINEAGR] known to be pure CD4 epitope.
- the two other epitopes are specific for the male antigen H-Y, one is the Dby epitope of amino acid sequence [NAGFNSNRANSSRSS] and the other one is Uty epitope of amino acid sequence [WMHHNMDLI], eGFP and polyepitopes are separated by a (G3S)a linker.
- Said polyepitopes fusion encoded into MVA is of nucleotide sequence as disclosed as SEQ ID NO: 12.
- the polyepitopes expressed amino acid sequence is disclosed as SEQ ID NO: 13.
- the expression cassette is under control of the poxviral promoter pH5R (SEQ ID NO: 14) and inserted in the deletion III locus.
- MVATG20014 is a MVA expressing a murine IL-12 (mlL-12) of the nucleotide sequence disclosed as SEQ ID NO: 11 under the control of the pllK7.5 promoter (SEQ ID NO: 15) and inserted in the deletion II locus.
- MVATG20014 is also expressing the same fusion eGFP-polyepitopes as MVATG20022.
- the expression cassette of the fusion is under the control of the poxviral promoter pH5R (SEQ ID NO: 14) and is inserted in the deletion III locus.
- MVA control or MVA ctr
- MVA ctr is a wild type MVA.
- Said wild type MVA is accessible via culture collections, like ATCC (e.g.: VR-1508TM).
- PCPV control or PCPV ctr
- PCPV ctr is a wild type PCPV (wild-type TJS strain as identified by ATCC reference number ATCC VR-634TM).
- EXAMPLE 1 IL-12 not induced by Poxviruses in human primary cells
- Cytokine secretion profiles notably of IFN alpha and Interleukin-12 (IL-12), were analysed in the supernatant of Human Peripheral Blood PBMCs cryopreserved from Cancer Donors (purchased from NeoBiotech via CliniSciences), infected with the human Orthopoxviruses VACV, the MVA, or the bovine Parapoxvirus PCPV (MOI of 0.3, incubation period 16 h).
- Luminex analysis showed that PCPV induced significantly higher secretion of IFN-alpha than MVA, and that VACV had no effect on IFN-alpha secretion.
- PCPV was considered a novel vector to enhance the therapeutic efficacy of antitumor vaccination (see Ramos et al. 2022).
- the absence of a clear IL-12 signals in infected PBMCs suggest that poxviral infection block this signalling pathway (compare effect of R848 in PBMCs).
- PCPTG19818 Schematic representation of the three different recombinant PCPVs (PCPTG19818; PCPTG19873; PCPTG19874) are shown on Figure 2.
- PCPTG19873 encodes five epitopes, among them one sequence known to be a pure CD8 epitope [SIINFEKL] and one sequence known to be a pure CD4 epitope [ISQAVHAAHAEINEAGR], Epitopes are separated by GSG linkers, the polyepitopes are preceded by a signal peptide for the endoplasmic reticulum (ER) and terminated by a subsequent FLAG tag (Flag HRP (horse radish peroxidase)).
- the expression cassette is under control of the poxviral promoter p7.5K and inserted in the VEGF loci.
- PCPTG19874 contains mlL12 and epitope encoding cassettes (polyepitopes) in a back-to-back orientation in relation to each other within the VEGF locus.
- PCPVs were generated and produced in bovine Bos Taurus Turbinate (BT) cells (ATCC CRL-1390) and purified as described in Ramos et al., 2022 and W02019/170820.
- HeLa cells were infected in triplicates at MOI 1 with the indicated virus. After 48 hours, supernatants were harvested for Luminex analysis (murine I L12 simplex assay, ThermoFisher), and cell extracts were prepared for Western Blot analysis (Figure 3).
- PCPV-encoded mlL12 (PCPTG19818)
- splenocytes were prepared from C57BL/6 mice and infected at MOI 0.3 and 1 in duplicates with a PCPV vaccine encoding for the murine IL-12 (PCPTG19818) or not encoding for IL-12 (PCPV Ctr).
- PCPTG19818 PCPV vaccine encoding for the murine IL-12
- PCPV Ctr PCPV Ctr
- Activated NK, CD4+T and CD8+T cells were detected after infection with both PCPV vectors, which confirms earlier results about PCPV-induced activation of NK and T cells (Ramos et al., 2022).
- PCPV- mlL12 caused an incremental increase of activated NK cells (1,4-fold), of CD8+ T cell (1,8- fold) and of CD4+ T cells (2,5-fold) compared to PCPV ctr.
- IFN gamma was only detected in supernatant from splenocytes infected with PCPV-mlL12.
- PBMCs were isolated from leukocyte concentrates by density gradient centrifugation using Ficoll-Paque PLUS (GE Healthcare) and infected at MOI 0.3 in duplicate, or treated with recombinant mlL12 (PeproTech 210-12) between 5 and 0,5 ng/ml. On the next day, supernatant was harvested, and cells were analyzed by flow cytometry (MACSQuant) to detect activated NK, CD4+T and CD8+ T cells.
- FCSQuant flow cytometry
- PCPV has shown efficacy in the murine tumor model MC38: PCPV primed specific T cell response without encoding a tumor antigen (Ramos et al, 2022).
- PCPV-mlL12 PCPTG19818
- PCPV-ctr At day 0, the colon carcinoma cell line MC38 (2x10 s cells), were grafted subcutaneously (sc) in the flank of 10 C57BL/6 mice. On day 2, 9 and 16, viruses were injected at the suboptimal dose of 5x10 s pfu into the tumors ( Figure 6).
- EXAMPLE 7 Activation of immune cells in draining lymph nodes day 1 after sc/itu injection
- DLN draining lymph nodes
- DLN from tumor bearing mice were collected and scratched through a cell strainer into culture medium.
- Cells were washed with phosphate-buffered saline (PBS) by centrifugation before the staining with antibodies including CD45 VioGreen (Miltenyi #130-110-665), CD3 PE Cy7 (BD Pharmingen #552774), FVS575V (BD Horizon #565694), CD8 FITC (BD Pharmingen #553030), CD4 APC Vio770 (Miltenyi #130-118-957), NKp46 R718 (BD Pharmingen #751865), PDL1*BV421 (BD Pharmingen #564716) and CD69**APC (Miltenyi #130-115-461).
- PBS phosphate-buffered saline
- Rat lgG2a Isotype control BV421 (BD Pharmingen #562965) and Control REA293 APC (Miltenyi #130-113-434) for 30 min at +4°C.
- Cells were washed with PBS and suspended in 100 pL MACSQuant Running Buffer for flow cytometry analysis. The following strategy of gating was used using the Kaluza 2.1.1 software (Beckman Coulter). Cells were identified by side scatter forward scatter (SSC vs FSC). From this gate, a dot plot (FVS757V vs SSC) was created to determine the Live cells (FVS575V negative).
- PCPV vectors increased the frequencies of activated NK and T cells.
- PCPV-mlL12 PCPTG19818
- MVA-ctr had little effects on NK cells and no effects on T cells.
- PCPV-mlL12 (PCPTG19818) augments survival and tumor control compared to PCPV-ctr. Cases of complete tumor rejection were observed.
- lxlO 7 pfu of a PCPV-ctr vector, or the polyepitopes encoding vectors PCPTG19873 and PCPTG19874 were injected days 0, 7 and 14 into the flank (subcutaneously) of C57BL/6 mice. At days 7, 14 and 45, blood was taken quantify CD8+ OVA-specific T cells. Spleens were harvested at the end of the experiment (day 45).
- a MHC-pentameric assay was used. Whole blood samples were collected into heparinized tubes. Whole blood was diluted in PBS EDTA 2mM and layered on lympholyte M separation cell media (TEBU BIO #CL5031), then centrifuged 1500xg 20 min at room temperature without brake. The enriched cell fraction of splenocytes at interphase was collected and transferred into 96 wells plate to proceed with the surface staining. Cells were washed with wash buffer (0.1% BSA in PBS) by centrifugation 5 min at 400xg.
- wash buffer (0.1% BSA in PBS
- Pellets were resuspended in wash buffer containing 10 pL/test of R-PE Pro MHC Pentamer H-2Kb SIINFEKL (Prolmmune #F093-2B-E) and incubated at +4°C for 30 min. Cells were washed with wash buffer (0.1% BSA in PBS) by centrifugation 5 min at 400xg. Pellets were resuspended in wash buffer containing CD8 APC (BD Pharmingen #553035) and CD19 V450 (BD Pharmingen #560376) and incubated for 30 min at +4°C. Cells were washed with wash buffer (0.1% BSA in PBS) by centrifugation 5 min at 400xg.
- PCPTG19873 PCPV encoding tumor epitopes
- PCPTG19874 PCPV encoding tumor epitopes and mlL12
- E.G7-OVA murine T lymphoblast cell line
- PCPTG19873 and PCPTG19874 vectors C57BL/6 mice were grafted with 3xl0 5 cells sc. Day 5, 12 and 19, lxlO 7 pfu of PCPV-ctr, PCPTG19873 or PCPTG19874 were injected into the growing tumors (10 mice per group). Tumor growth and survival proportions were monitored.
- EXAMPLE 10 Detection of murine IL12 in extracellular vesicle (EV) fraction isolated from infected PBMCs.
- PBMCs from a healthy donor were cultivated in RPMI, supplemented with 1% glutamine and 1% gentamicin, and 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- the serum was pretreated by ultracentrifugation o/n at 100 000 g to eliminate serum inherent EVs.
- 1X10 8 PBMCS were infected in 35 ml with PCPV-mlL12 (PCPTG19818) at the MOI of 1, or virus was added to cell-free medium. Next day, the cultures were centrifuged at 300 g, then 2000 g. The cleared supernatants were concentrated using a Centricon 70-Plus, membrane Ultracel-PL, 10 kD (Merck Millipore) to a volume of 2 ml. This solution was filtered using Ultrafree-CL Centrifugal Filter 0.1 pm pore size (Merck Millipore).
- mlL12 was quantified in various fractions of the EV isolation procedure by Luminex (mlL12 Simplex) ( Figure 10). Compared to the cell-free control, mlL12 increased in the various fractions. This observation suggests that virus infection and mlL12 gene expression occurred in infected PBMC cultures.
- mlL12 was readily detected in the EV fraction. This suggests that mlL12 was associated with EVs and such modified EVs associated with IL-12 can exert activation of target cells such as, but not limited to, pDCs, NK, B cells.
- PCPV-OVA vectors encoding IL12 (PCPTG19874) or not (PCPTG19873), by intracellular cytokine staining (ICS): lxlO 7 pfu of a PCPV ctr vector, wherein said polyepitopes encoding vectors PCPTG19873 and PCPTG19874 were injected days 0, 7 and 14 into the flank (subcutaneously) of naive C57BL/6 mice. After 45 days, mice were sacrificed, and splenocytes were isolated. Frozen splenocytes were thawed, cultivated, and stimulated for 5 hours in the presence of OVA specific peptide SIINFEKL or appropriate controls. The percentage of live CD8+ T cells secreting IFN-gamma is shown in Figure 12.
- Splenocytes (lxlOE 6 cells), harvested from three different immunized mice were incubated for 4-6 hours with lpg/ml OVA peptide (ProteoGenix NH2-SIINFEKL-COOH) or irrelevant peptide (ProteoGenix NH2-KNGENAQAI-COOH) in RPMI 1640 media containing 10 % FBS.
- Golgi Stop (BD #554724)
- Golgi Plug (BD #555029) were added to block cytokine release.
- splenocytes were stained with surface antibodies CD3 PerCP Cy5.5 (BD Pharmingen #551163) and CD8 V500 (BD Horizon #560776) and with Live Dead Violet (Invitrogen #L34958) for viability, in phosphate- buffered saline (PBS) 20 min at +4°C.
- Splenocytes were then treated with fixation buffer and permeabilization buffer following the manufacturer's protocol (Becton Dickinson Cytofix/CytopermTM Fixation/Permeabilization Solution Kit # 554714) and intracellularly stained for interferon gamma (IFNy-FITC (BD Pharmingen #554411) 30 min at +4°C.
- fixation buffer and permeabilization buffer following the manufacturer's protocol (Becton Dickinson Cytofix/CytopermTM Fixation/Permeabilization Solution Kit # 554714) and intracellularly stained for interferon gamma (IFNy-FITC (BD Pharmingen #
- results show that the highest percentage IFN-gamma secreting CD8+ T cells were detected after stimulation with the OVA-peptide SIINFEKL in splenocytes from mice vaccinated with PCPTG19874 (PCPV-OVA-IL12).
- PCPTG19874 PCPV-OVA-IL12 induces an IFN-gamma secreting CD8+ T cells response at least as twice superior.
- EXAMPLE 12 Comparison of therapeutic vaccination with PCPV-OVA and PCPV-OVA-IL12 versus MVA-OVA and MVA-0VA-IL12 after repeated subcutaneous injections
- PCPV and MVA-based therapeutic vaccines were compared in an OVA-specific tumor model E.G7- OVA.
- C57BL/6 mice were grafted with 3xl0 5 cells sc.
- PCPV and MVA backbones were comparable. Tumor growth was better controlled after subcutaneous treatment with PCPV-OVA-IL12 compared to PCPV-OVA. Same observation was made for MVA-0VA-IL12 and MVA-OVA.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention relève du domaine de l'immunothérapie virale. En particulier, l'invention concerne un nouveau virus de la paraviccine recombinant (PCPV) comprenant une molécule d'acide nucléique insérée dans son génome et codant pour une interleukine-12, une composition de celui-ci ainsi que leur utilisation thérapeutique pour prévenir ou traiter des maladies, et, notamment, des maladies prolifératives comme les cancers. La présente invention concerne également des procédés de génération et d'amplification d'un tel PCPV et un procédé de déclenchement ou de stimulation et/ou de réorientation d'une réponse immunitaire à l'aide d'un tel PCPV. Dans un mode de réalisation, le PCPV recombinant selon l'invention code en outre pour un polypeptide antigénique hétérologue. L'invention peut être largement utilisée pour la vaccination thérapeutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22306410.6 | 2022-09-23 | ||
EP22306410 | 2022-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024062098A1 true WO2024062098A1 (fr) | 2024-03-28 |
Family
ID=83902790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/076224 WO2024062098A1 (fr) | 2022-09-23 | 2023-09-22 | Virus de la paraviccine recombinant codant pour l'interleukine-12 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024062098A1 (fr) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032029A1 (fr) | 1996-02-28 | 1997-09-04 | Bayer Aktiengesellschaft | Parapoxvirus contenant de l'adn etranger, leur production et leur utilisation dans des vaccins |
WO1997037031A1 (fr) | 1996-03-29 | 1997-10-09 | University Of Otago | Vecteurs de parapoxvirus |
WO2006005529A1 (fr) | 2004-07-13 | 2006-01-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus combines a d'autres agents antiviraux dans le traitement du vih/sida |
WO2012001145A1 (fr) | 2010-07-01 | 2012-01-05 | Novozymes A/S | Blanchiment de pâte |
WO2017060360A1 (fr) * | 2015-10-06 | 2017-04-13 | Invectys | Constructions de polyépitopes à utiliser en immunothérapie |
WO2018209194A2 (fr) * | 2017-05-12 | 2018-11-15 | Icahn School Of Medicine At Mount Sinai | Virus de la maladie de newcastle et leurs utilisations |
WO2018234506A2 (fr) | 2017-06-21 | 2018-12-27 | Transgene Sa | Vaccin personnalisé |
WO2019170820A1 (fr) | 2018-03-07 | 2019-09-12 | Transgene | Vecteurs de parapoxvirus |
-
2023
- 2023-09-22 WO PCT/EP2023/076224 patent/WO2024062098A1/fr unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032029A1 (fr) | 1996-02-28 | 1997-09-04 | Bayer Aktiengesellschaft | Parapoxvirus contenant de l'adn etranger, leur production et leur utilisation dans des vaccins |
US6365393B1 (en) | 1996-02-28 | 2002-04-02 | Bayer Aktiengesellschaft | Parapoxviruses containing foreign DNA, their production and their use in vaccines |
WO1997037031A1 (fr) | 1996-03-29 | 1997-10-09 | University Of Otago | Vecteurs de parapoxvirus |
US20030013076A1 (en) | 1996-03-29 | 2003-01-16 | University Of Otago | Parapoxvirus vectors |
WO2006005529A1 (fr) | 2004-07-13 | 2006-01-19 | Aicuris Gmbh & Co. Kg | Parapoxvirus combines a d'autres agents antiviraux dans le traitement du vih/sida |
WO2012001145A1 (fr) | 2010-07-01 | 2012-01-05 | Novozymes A/S | Blanchiment de pâte |
WO2017060360A1 (fr) * | 2015-10-06 | 2017-04-13 | Invectys | Constructions de polyépitopes à utiliser en immunothérapie |
WO2018209194A2 (fr) * | 2017-05-12 | 2018-11-15 | Icahn School Of Medicine At Mount Sinai | Virus de la maladie de newcastle et leurs utilisations |
WO2018234506A2 (fr) | 2017-06-21 | 2018-12-27 | Transgene Sa | Vaccin personnalisé |
WO2019170820A1 (fr) | 2018-03-07 | 2019-09-12 | Transgene | Vecteurs de parapoxvirus |
Non-Patent Citations (34)
Title |
---|
"Genbank", Database accession no. GQ329670 |
BLOCK ET AL., IN: PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 2022 |
CANCER RES, vol. 80, no. 16, 2020, pages 4566 |
CANCER RES, vol. 82, no. 12, 2022, pages CT182 |
CATTANEORUSSELL, PLOS PATHOGENS, 2017 |
CHOI ET AL., SURGERY., vol. 163, no. 2, February 2018 (2018-02-01), pages 336 - 342 |
DAYHOFFED, SUPPL., vol. 3, 1981, pages 482 - 9 |
DELORD ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022, pages 2637 - 2637 |
FENNER, VETERINARY VIROLOGY, 2017 |
FRIEDMAN-KIEN ET AL., SCIENCE, vol. 140, 1963, pages 1335 - 6 |
GOMEZ ET AL., EXPERT REV VACCINES, vol. 12, no. 12, 2013, pages 1395 - 1416 |
HAUTANIEMI ET AL., J. GEN. VIROL., vol. 91, 2010, pages 1560 - 76 |
KAUFMAN ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 14, 2015, pages 642 - 661 |
LEONARD ET AL., BLOOD., vol. 90, no. 7, 1 October 1997 (1997-10-01), pages 2541 - 8 |
LEWIS ND ET AL., MOL CANCER THER., vol. 20, no. 3, March 2021 (2021-03-01), pages 523 - 534 |
LIESCHKE ET AL., NAT BIOTECHNOL., vol. 15, no. 1, pages 35 - 40 |
LIESCHKE ET AL., NATURE BIOTECHNOLOGY, 1997 |
LIN ET AL., NAT CANCER, vol. 3, 2022, pages 911 - 926 |
MALONE ET AL., IN: PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 2020 |
MANETTI ET AL., J EXP MED., vol. 177, no. 4, 1 April 1993 (1993-04-01), pages 1199 - 204 |
NEEDLEMANWUNSCH, J.MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
NGUYEN ET AL., FRONT IMMUNOL., vol. 11, 15 October 2020 (2020-10-15), pages 575597 |
PIERCE ET AL., FRONT CELL INFECT MICROBIOL., 2020 |
RAMOS ET AL., CLIN TRANSL IMMUNOLOGY., vol. 11, no. 5, 8 May 2022 (2022-05-08), pages e1392 |
RAMOS R N ET AL: "Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination", CLINICAL & TRANSLATIONAL IMMUNOLOGY, vol. 11, no. 5, 1 January 2022 (2022-01-01), GB, XP093107453, ISSN: 2050-0068, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cti2.1392> DOI: 10.1002/cti2.1392 * |
RINTOUL ET AL., MOL. THER., vol. 20, no. 6, 2012, pages 1148 - 57 |
RIZZA ET AL., AUTOIMMUNITY., vol. 43, no. 3, April 2010 (2010-04-01), pages 204 - 9 |
ROOIJ ET AL., VACCINE, vol. 28, no. 7, 2010, pages 1808 - 13 |
SCHULZE ET AL., VET MICROBIOL., vol. 137, 2009, pages 260 - 7 |
TIKKANEN ET AL., J. GEN. VIROL., vol. 85, 2004, pages 1413 - 8 |
TUGUES S ET AL., CELL DEATH DIFFER., 2015 |
VAN VLOTEN ET AL., J IMMUNOTHER CANCER, vol. 10, 2022, pages e004335 |
VON BUTTLAR ET AL., PLOS ONE, vol. 9, no. 8, 2014, pages e106188 |
WANG ET AL., FRONT CELL INFECT MICROBIOL., vol. 12, 25 July 2022 (2022-07-25), pages 910466 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11285209B2 (en) | Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors | |
RU2725799C2 (ru) | Онколитические аденовирусы, кодирующие биспецифические антитела, а также способы и применения, связанные с ними | |
WO2010030002A1 (fr) | Cellule capable d'exprimer un ligand gitr exogène | |
CN112533942A (zh) | 嵌合抗原受体细胞疗法中细胞因子释放综合征的抑制 | |
TWI830771B (zh) | 包含核酸及car修飾的免疫細胞的治療劑及其應用 | |
CN116162654A (zh) | 用于癌症免疫疗法的重组痘病毒 | |
WO2019080537A1 (fr) | Agent thérapeutique comprenant un virus oncolytique et des cellules tueuses naturelles-récepteur antigénique chimérique, utilisation, kit, et méthode de traitement d'une tumeur et/ou d'un cancer | |
US20210023151A1 (en) | Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy | |
WO2021239020A1 (fr) | Procédé d'immunothérapie pour combiner un récepteur d'antigène chimère et un interféron de type i et application de celui-ci | |
US20230002465A1 (en) | Vaccinia viruses and methods for using vaccinia viruses | |
JP2024050588A (ja) | パラポックスウイルスベクター | |
CN113416260A (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
Abboud et al. | Transcription factor Bcl11b controls effector and memory CD8 T cell fate decision and function during poxvirus infection | |
JP2019520840A (ja) | マルチウイルス特異的t細胞免疫療法 | |
JP2022512595A (ja) | 組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
Sanos et al. | NLRC4 inflammasome-driven immunogenicity of a recombinant MVA mucosal vaccine encoding flagellin | |
JP2020531524A (ja) | 組み換えmva及び抗体の静脈内投与を用いた、がん治療のための併用療法 | |
WO2024062098A1 (fr) | Virus de la paraviccine recombinant codant pour l'interleukine-12 | |
US11364267B1 (en) | Bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells, preparation method and application thereof | |
RU2779987C2 (ru) | Персонализированная вакцина | |
WO2020154889A1 (fr) | Combinaison d'anticorps présentant un mutant fc et une cellule effectrice, utilisation correspondante et procédé de préparation associé | |
WO2024130212A1 (fr) | Virus de la vaccine recombinant codant pour des un ou plusieurs inhibiteurs de cellules tueuses naturelles et de lymphocytes t | |
WO2023118508A1 (fr) | Virus mva recombinants pour administration intrapéritonéale pour le traitement du cancer | |
CN111996171A (zh) | 一种基于特异性免疫细胞的肿瘤免疫治疗组合物、制备方法和应用 | |
KR20200026894A (ko) | 개인 맞춤형 백신 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23773320 Country of ref document: EP Kind code of ref document: A1 |